Sex, female
|
24 (80%)
|
29 (61.7%)
|
2.48 (0.85–7.24)
|
0.096
|
4.96 (1.24–19.87)
|
0.024
|
Age (years), median (IQR)
|
61 (43–65)
|
65 (51–72)
|
0.98 (0.95–1.01)
|
0.247
|
0.98 (0.94–1.02)
|
0.297
|
Race
|
Caucasian
|
22 (73.3%)
|
29 (61.7%)
|
1.71 (0.63–4.64)
|
0.295
| | |
South Asian
|
1 (3.3%)
|
1 (2.1%)
|
1.59 (0.09–26.36)
|
0.748
| | |
East Asian
|
6 (20%)
|
16 (34%)
|
0.48 (0.16–1.42)
|
0.188
|
0.24 (0.06–0.95)
|
0.042
|
African
|
1 (3.3%)
|
1 (2.1)
|
1.59 (0.09–26.36)
|
0.748
| | |
Weekly dose AK per bodyweight (mg/kg/week), median (IQR)b
|
29 (23.7–41.3)
|
25.2 (21.8–29.4)
|
1.05 (1.00–1.10)
|
0.047
|
1.03 (0.98–1.09)
|
0.248
|
Months on AK, median (IQR)
|
11.5 (7–18.25)
|
7 (4–10)
|
1.04 (1.00–1.08)
|
0.052
| | |
Total dose AK per bodyweight (g/kg), Median (IQR)c
|
1.81 (0.85–3.13)
|
0.74 (0.51–1.27)
|
1.59 (1.08–2.33)
|
0.018
|
1.62 (1.08–2.43)
|
0.020
|
Total dose AK (g), Median (IQR)d
|
77.3 (52.9–196.3)
|
41.7 (25.6–67.5)
|
1.01 (1.00–1.02)
|
0.011
| | |
Repeated exposure to amikacin
|
9 (30%)
|
10 (21.3%)
|
1.59 (0.56–1.52)
|
0.388
| | |
Baseline weight (kg), Median (IQR)
|
51.5 (41–66.5)
|
55 (48–64)
|
0.99 (0.96–1.03)
|
0.712
| | |
Initial serum creatinine (umol/L), mean (SD)
|
66.0 (56.7–74.0)
|
63 (53–75)
|
1.01 (0.97–1.04)
|
0.656
| | |
Baseline disabling hearing impairment
|
8 (26.7%)
|
24 (51.1%)
|
0.35 (0.13–0.94)
|
0.037
|
0.54 (0.17–1.74)
|
0.305
|
Current treatment with macrolides
|
29 (96.7%)
|
45 (95.7%)
|
1.23 (0.11–14.87)
|
0.839
| | |
Nephrotoxicity
|
1 (3.6%)
|
4 (8.5%)
|
0.38 (0.04–3.58)
|
0.398
| | |